Literature DB >> 16232020

Effects of perioperative antiinflammatory and immunomodulating therapy on surgical wound healing.

Anthony J Busti1, Justin S Hooper, Christopher J Amaya, Salahuddin Kazi.   

Abstract

Patients with various rheumatologic and inflammatory disease states commonly require drugs known to decrease the inflammatory or autoimmune response for adequate control of their condition. Such drugs include nonsteroidal antiinflammatory drugs (NSAIDs), cyclooxygenase (COX)-2 inhibitors, corticosteroids, disease-modifying antirheumatic drugs (DMARDs), and biologic response modifiers. These drugs affect inflammation and local immune responses, which are necessary for proper wound healing in the perioperative setting, thereby potentially resulting in undesirable postoperative complications. Such complications include wound dehiscence, infection, and impaired collagen synthesis. The end result is delayed healing of soft tissue and bone wounds. The current literature provides insight into the effect of some of these drugs on wound healing. For certain drugs, such as methotrexate, trials have been conducted in humans and direct us on what to do during the perioperative period. Whereas with other drugs, we must rely on either small-animal studies or extrapolation of data from human studies that did not specifically look at wound healing. Unfortunately, no clear consensus exists on the need and optimum time for withholding therapy before surgery. Likewise, clinicians are often uncertain of the appropriate time to resume therapy after the procedure. For those drugs with limited or no data in this setting, the use of pharmacokinetic properties and biologic effects of each drug should be considered individually. In some cases, discontinuation of therapy may be required up to 4 weeks before surgery because of the long half-lives of the drugs. In doing so, patients may experience an exacerbation or worsening of disease. Clinicians must carefully evaluate individual patient risk factors, disease severity, and the pharmacokinetics of available therapies when weighing the risks and benefits of discontinuing therapy in the perioperative setting.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16232020     DOI: 10.1592/phco.2005.25.11.1566

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  46 in total

1.  Suppressed wound healing in a patient with rheumatoid arthritis taking leflunomide (arava).

Authors:  D Miller Wise
Journal:  Perm J       Date:  2011

Review 2.  [Multimodal oncological therapy concepts, chemotherapy and immunosuppressive drugs: effects on surgical morbidity and mortality].

Authors:  A K Berger; D Jäger
Journal:  Chirurg       Date:  2013-11       Impact factor: 0.955

Review 3.  The effect of nonsteroidal anti-inflammatory drugs on tissue healing.

Authors:  Michael R Chen; Jason L Dragoo
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2012-06-29       Impact factor: 4.342

4.  Postoperative infliximab is not associated with an increase in adverse events in Crohn's disease.

Authors:  Miguel Regueiro; Sandra El-Hachem; Kevin E Kip; Wolfgang Schraut; Leonard Baidoo; Andrew Watson; Jason Swoger; Marc Schwartz; Arthur Barrie; Marilyn Pesci; David Binion
Journal:  Dig Dis Sci       Date:  2011-06-17       Impact factor: 3.199

5.  The salvage of knee-exposed prosthesis using neurofasciocutaneous sural flap.

Authors:  L Vaienti; A Menozzi; J Lonigro; M Soresina; G Ravasio
Journal:  Musculoskelet Surg       Date:  2010-03-05

Review 6.  Prophylactic negative pressure wound therapy in colorectal surgery. Effects on surgical site events: current status and call to action.

Authors:  Gianluca Pellino; Guido Sciaudone; Francesco Selvaggi; Silvestro Canonico
Journal:  Updates Surg       Date:  2015-04-29

7.  The neurosurgical wound and factors that can affect cosmetic, functional, and neurological outcomes.

Authors:  James A D Berry; Dan E Miulli; Benjamin Lam; Christopher Elia; Julia Minasian; Stacey Podkovik; Margaret R S Wacker
Journal:  Int Wound J       Date:  2018-09-24       Impact factor: 3.315

8.  Immunologically restricted patients exhibit a pronounced inflammation and inadequate response to hypoxia in fracture hematomas.

Authors:  Paula Hoff; T Gaber; K Schmidt-Bleek; U Sentürk; C L Tran; K Blankenstein; S Lütkecosmann; J Bredahl; H J Schüler; P Simon; G Wassilew; F Unterhauser; G R Burmester; G Schmidmaier; C Perka; G N Duda; F Buttgereit
Journal:  Immunol Res       Date:  2011-10       Impact factor: 2.829

9.  C-reactive protein +1444CT (rs1130864) genetic polymorphism is associated with the susceptibility to systemic lupus erythematosus and C-reactive protein levels.

Authors:  Francieli Delongui; Marcell Allyson Batisti Lozovoy; Tatiana Mayiumi Veiga Iriyoda; Neide Tomimura Costa; Nicole Perugini Stadtlober; Daniela Frizon Alfieri; Tamires Flauzino; Isaias Dichi; Andréa Name Colado Simão; Edna Maria Vissoci Reiche
Journal:  Clin Rheumatol       Date:  2017-06-01       Impact factor: 2.980

Review 10.  Treating skeletal pain: limitations of conventional anti-inflammatory drugs, and anti-neurotrophic factor as a possible alternative.

Authors:  Cory J Xian; Xin-Fu Zhou
Journal:  Nat Clin Pract Rheumatol       Date:  2009-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.